This lecture will discuss the mechanism of CCM® Therapy and the clinical evidence behind this recently FDA approved technology for NYHA Class III HF patients. The faculty will discuss the therapy benefits and emphasize the importance of patient screening and NYHA Classification for patients being treated for Heart Failure. Optimizer® is designed to improve overall heart function and quality of life for patients living with heart failure. The faculty will share their experiences and what they have learned about CCM® therapy and give case-based examples of how you can determine patients that may be eligible for this device treatment option.
The Ohio State University Wexner Medical Center
Credits: None available.
You must be logged in and own this session in order to